CLDN 18.2

CLDN18.2:
test and interpret with confidence

Help identify a specific subpopulation of patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma to guide treatment approaches.

CLDN18.2:
test and interpret with confidence
CLDN18.2:
test and interpret with confidence

What is CLDN18.2?

CLDN18.2 is an actionable, predictive biomarker in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.1

What is CLDN18.2?
What is CLDN18.2?

Preparing and testing
for CLDN18.2

Learn more about testing for CLDN18.2, including the impact of preanalytical factors on staining, the importance of antibody selection, and the significance of reflexive CLDN18.2 testing upon diagnosis.

Preparing and testing for CLDN18.2
Preparing and testing for CLDN18.2

Interpretation of CLDN18 staining

Accurate CLDN18 staining interpretation is critical to guide treatment decision-making.

IHC interpretation of CLDN18.2 expression
IHC interpretation of CLDN18.2 expression

Reporting test results

Review best practices for accurate and consistent reporting of CLDN18.2 expression and positivity.

Reporting test results
Reporting test results

Stain gallery and quiz

Review and test your interpretative pathology skills through matched, consensus-scored, whole-slide images.

Stain gallery and quiz
Stain gallery and quiz

CLDN18.2 resources and expert videos

Download additional resources to learn more about how to consistently test, interpret, and report CLDN18.2 in G/GEJ cancer.

CLDN18.2 resources
CLDN18.2 resources

Reference:

  • 1.Fassan M, Kuwata T, Matkowskyj KA, et al. Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach. Mod Pathol. 2024;37(11):100589.